

ESPI Current Report

Number: 9/2022
Date of preparation: 5 April 2022 roku
Company: XTPL S.A., a joint stock company with its registered office in Wrocław

Title: Signing an agreement with the US company nScript for the sale XTPL's conductive nanopaste CL85

Legal basis: Article 17(1) MAR – inside information

Content:

The Management Board of XTPL S.A. ("Issuer", "Company", "XTPL") reports that on 5 April 2022 an agreement was signed between the Issuer and the US company nScript, Orlando, Florida ("nScript"), providing for the sale of conductive nanopaste CL85 developed and produced by XTPL ("Agreement").

Under the Agreement, the nanopaste produced by the Issuer will be distributed by nScript to its customers under the nScript brand.

Since 2002, nScript has designed and manufactured high-precision microdispensing equipment for printed electronics, electronics packaging, solar cell metallization, communications, 3D printing and bioprinting. Its customers include military, academic and research institutes, government agencies and national labs, as well as privately-owned technology corporations. NScript technological solutions are used by manufacturers from the medical, defense and space sectors.

The commencement of the Company's cooperation with the US manufacturer in relation to the sale of Ag Nanopaste CL85 confirms the market potential for the conductive materials produced by the Issuer. The Agreement may have a significant impact on the Company's future financial results.

Accordingly, in the Management Board's opinion, the information on conclusion of the Agreement meets the criteria of inside information within the meaning of Article 7(1) MAR.

Signatures of the Company's representatives:

Jacek Olszański
MANAGEMENT BOARD MEMBER

XTPL S.A.
Stabłowicka 147
54-066 Wrocław
xtpl.com



shaping global nanofuture